Epstein-Barr virus vaccine: A cytotoxic T-cell-based approach

Expert Review of Vaccines

Volumn 1, Issue 4, 2002, Pages 467-476

  Bharadwaj, Mandvi ^a   Moss, Denis J ^b  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^b NONE

Author keywords

Cytotoxic T lymphocytes; Epitope; Epstein Barr virus; Infectious mononucleosis; Latent infection; Nasopharyngeal carcinoma; Polytope; Post transplant lymphoproliferative disease; Therapeutic vaccine

Indexed keywords

CELL NUCLEUS ANTIGEN; EPITOPE; EPSTEIN BARR VIRUS NUCLEAR ANTIGEN; EPSTEIN BARR VIRUS VACCINE; LATENT MEMBRANE PROTEIN 1; LATENT MEMBRANE PROTEIN 2A; LATENT MEMBRANE PROTEIN 2B; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROTEIN BHRF1; PROTEIN BMLF1; PROTEIN BMRF1; PROTEIN GP350; PROTEIN GP85; RECOMBINANT PROTEIN; RECOMBINANT VACCINE; STRUCTURAL PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS VECTOR;

ANTIGEN EXPRESSION; CANCER; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; EPSTEIN BARR VIRUS; GEOGRAPHY; HUMAN; IMMUNOTHERAPY; MONONUCLEOSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; VACCINE PRODUCTION; VIRUS INFECTION;

ANIMALS; EPITOPES; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VIRAL VACCINES;

EID: 0012920101     PISSN: 14760584     EISSN: None     Source Type: Journal    
DOI: 10.1586/14760584.1.4.467     Document Type: Review

References (47)

1. Niedobitek G, Agathanggelou A, Steven N, Young LS. Epstein-Barr virus (EBV) in infectious mononucleosis: detection of the virus in tonsillar B-lymphocytes but not in desquamated oropharyngeal epithelial cells. Mol. Pathol. 53(1), 37-42 (2000).
2. Karajannis MA, Hummel M, Anagnostopoulos I, Stein H. Strict lymphotropism of Epstein-Barr virus during acute infectious mononucleosis in nonimmunocompromised individuals. Blood 89(8), 2856-2862 (1997).
3. Rickinson AB, Moss DJ. Human cytotoxic T-lymphocyte responses to Epstein-Barr virus infection. Ann. Rev. Immunol. 15, 405-431 (1997). Extensive review of CTL response to EBV.
4. Kieff E. Epstein-Barr virus and its replication. In: Field's Virology. Fields BN, Knipe DM and Howley PM (Eds). Lippincott-Raven, Philadelphia, PA, USA, 2343-2396 (1996). General overview of EBV replication and the different viral proteins.
5. Speck SH, Chatila T, Flemington E. Reactivation of Epstein-Barr virus: regulation and function of the BZLF1 gene. Trends Microbiol. 5, 399-405 (1997).
6. Edson CM, Thorley-Lawson DA. Epstein-Barr virus membrane antigens: characterization, distribution and strain differences. J. Virol. 39, 172-184 (1981).
7. Klein G. EBV and B-cell Lymphomas. In: Herpesviruses and Immunity. Medveczky PG, Friedman H, Bendinelli M (Eds). Plenum, New York, NY, USA, 165-190 (1998).
8. Murray PG, Young LS. The Role of the Epstein-Barr virus in human disease. Front. Biosci. 7, D519-540 (2002).
9. Chiang AK, Chan AC, Srivastava G, Ho FC. Nasal T/natural killer (NK)-cell lymphomas are derived from Epstein-Barr virus-infected cytotoxic lymphocytes of both NK- and T-cell lineage. Int. J. Cancer 73, 332-338 (1997).
10. Shibata D, Weiss LM. Epstein-Barr virus-associated gastric adenocarcinoma. Am. J. Pathol. 140, 769-774 (1992).
11. Webster-Cyriaque J, Middeldorp J, Raab-Traub N. Hairy leukoplakia: an unusual combination of transforming and permissive Epstein-Barr virus infections. J. Virol. 74, 7610-7618 (2000).
12. Deshpande CG, Badve S, Kidwai N, Longnecker R. Lack of expression of the Epstein-Barr Virus (EBV) gene products, EBERs, EBNA1, LMP1 and LMP2A, in breast cancer cells. Lab. Invest. 82(9), 1193-1199 (2002).
13. Levitskaya J, Coram M, Levitsky V et al. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 375, 685-688 (1995). Lack of processing and recongition of Epstein-Barr virus nuclear antigen.
14. Nikiforow S, Bottomly K, Miller G. CD4+ T-cell effectors inhibit Epstein-Barr virus-induced B-cell proliferation. J. Virol. 75(8), 3740-3752 (2001).
15. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. T-cell help for cytotoxic T-lymphocytes is mediated by CD40-CD40L interactions. Nature 393, 480-483 (1998).
16. Kalams SA, Walker BD. The critical need for CD4 help in maintaining effective cytotoxic T-lymphocyte responses. J. Exp. Med. 188, 2199-2204 (1998).
17. Rooney CM, Smith CA, Ng CY et al. Use of gene-modified virus-specific T-lymphocytes to control Epstein-Barr-virus- related lymphoproliferation. Lancet 345, 9-13 (1995). Adoptive transfer of CD8+ CTL resolves lymphomas in patients.
18. Khanna R, Bell S, Sherritt M et al. Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T-cells in solid organ transplant patients with posttransplant lymphoproliferative disease. Proc. Natl Acad. Sci. 96(18), 10391-10396 (1999). Adoptive transfer of CD8+ CTL resolves post-transplant lymphoproliferative disease in patients.
19. Rooney CM, Roskrow MA, Suzuki N, Ng CY, Brenner MK, Heslop H. Treatment of relapsed Hodgkin's disease using EBV-specific cytotoxic T-cells. Ann. Oncol. S129-132 (1998). Adoptive transfer of CD8+ CTL resolves Hodgkin's disease in patients.
20. Callan MF, Annels N, Steven N et al. T-cell selection during the evolution of CD8+T-cell memory in vivo. Eur. J. Immunol. 28, 4382-4390 (1998).
21. Tan LC, Gudgeon N, Annels NE et al. A re-evaluation of the frequency of CD8+ T-cells specific for EBV in healthy virus carriers. J. Immunol. 162, 1827-1835 (1999). CTL response in healthy virus carriers.
22. Bharadwaj M, Burrows SR, Burrows JM, Moss DJ, Catalina M, Khanna R. Longitudinal dynamics of antigen-specific CD8+ cytotoxic T-lymphocytes following primary Epstein-Barr virus infection. Blood 98, 2588-2589 (2001). Dynamics of CTL response during infectious mononucleosis and its implications.
23. Lechner F, Wong DK, Dunbar PR et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J. Exp. Med. 191, 1499-1512 (2000).
24. Farrell PJ, Hollyoake M, Niedobitek G, Agathanggelou A, Morgan A, Wedderburn N. Direct demonstration of persistent Epstein-Barr virus gene expression in peripheral blood of infected common marmosets and analysis of virus-infected tissues in vivo. J. Gen. Virol. 78(6), 1417-1424 (1997).
25. Moghaddam A, Rosenzweig M, Lee-Parritz D, Annis B, Johnson RP, Wang F. An animal model for acute and persistent Epstein-Barr virus infection. Science 276(5321), 2030-2033 (1997).
26. Bharadwaj M, Sherritt M, Khanna R, Moss DJ. Contrasting Epstein-Barr virus-specific cytotoxic T-cell responses to HLA A2-restricted epitopes in humans and HLA transgenic mice: implications for vaccine design. Vaccine 19, 3769-3777 (2001). CTL response in healthy virus carriers and mice - implications of natural infection versus immunization.
27. Khanna R, Sherritt M, Burrows SR. EBV structural antigens, gp350 and gp85, as targets for ex vivo virus-specific CTL during acute infectious mononucleosis: potential use of gp350/gp85 CTL epitopes for vaccine design. J. Immunol 162(5), 3063-3069 (1999).
28. Flano E, Woodland DL, Blackman MA. A mouse model for infectious mononucleosis. Immunol. Res. 25(3), 201-217 (2002).
29. Arrand JR, Prospects for a vaccine against Epstein-Barr virus. Cancer J. 5, 188-193 (1992).
30. Morgan AJ. Epstein-Barr virus vaccines. Vaccine 10, 563-571 (1992).
31. Gu SY, Huang TM, Ruan L et al. First EBV vaccine trial in humans using recombinant vaccina virus expressing the major membrane antigen. Dev. Biol. Stand. 84, 171-177 (1995).
32. Epstein MA, Randle BJ, Finerty S, Kirkwood JK. Not all potently neutralizing, vaccine-induced antibodies to Epstein-Barr virus ensure protection of susceptible experimental animals. Clin. Exp. Immunol. 63(3), 485-490 (1986).
33. Wilson AD, Lovgren-Bengtsson K, Villacres-Ericsson M, Morein B, Morgan AJ. The major Epstein-Barr virus (EBV) envelope glycoprotein gp340 when incorporated into Iscoms primes cytotoxic T-cell responses directed against EBV lymphoblastoid cell lines. Vaccine 17, 1282-1290 (1999).
34. Moss DJ, Schmidt C, Elliott S, Suhrbier A, Burrows S, Khanna R. Strategies involved in developing an effective vaccine for EBV-associated diseases. Adu Cancer Res. 69, 213-245 (1996).
35. Thomson SA, Elliott SL, Sherritt MA et al. Recombinant polyepitope vaccines for the delivery of multiple CD8 cytotoxic T-cell epitopes. J. Immunol. 157(2), 822-826 (1996). Delivery of multiple CTL epitopes by polytope technology.
36. Munz C, Bickham KL, Subklewe M et al. Human CD4(+) T-lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1. J. Exp. Med. 191(10), 1649-1660 (2000).
37. Lee SP, Constandinou CM, Thomas WA et al. Antigen presenting phenotype of Hodgkin Reed-Sternberg cells: analysis of the HLA class I processing pathway and the effects of interleukin-10 on epstein-barr virus-specific cytotoxic T-cell recognition. Blood 92, 1020-1030 (1998).
38. Khanna R, Busson P, Burrows SR et al. Molecular characterization of antigen-processing function in nasopharyngeal carcinoma (NPC): evidence for efficient presentation of Epstein-Barr virus cytotoxic T-cell epitopes by NPC cells. Cancer Res. 58, 310-304 (1998).
39. Frisan T, Sjoberg J, Dolcetti R et al. Local suppression of Epstein-Barr virus (EBV)-specific cytotoxicity in biopsies of EBV-positive Hodgkin's disease. Blood 86(4), 1493-1501 (1995).
40. Dukers DF, Jaspars LH, Vos W et al. Quantitative immunohistochemical analysis of cytokine profiles in Epstein-Barr virus-positive and -negative cases of Hodgkin's disease. J. Pathol. 190(2), 143-149 (2000).
41. Sing AP, Ambinder RF, Hong DJ et al. Isolation of Epstein-Barr virus (EBV)-specific cytotoxic T-lymphocytes that lyse Reed-Sternberg cells: implications for immune-mediated therapy of EBV+ Hodgkin's disease. Blood 89(6), 1978-1986 (1997).
42. Kuby J. Immunology 3rd Edition. WH Freeman (Ed.) New York, NY, USA, (1997).
43. Rowe M, Khanna R, Jacob CA et al. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: co-ordinate upregulation of peptide transporters and HLA-class I antigen. Eur. J. Immunol. 25(5), 1374-1384 (1995).
44. Sette A, Sidney J. Nine major HLA class I super types account for the vast preponderance of HLA-A and -B polymorphism. Immunogenetics 50(3-4), 201-212 (1999). Discusses the human leukocyte antigen (HLA) supertype concept.
45. Khanna R, Burrows SR, Nicholls J, Poulsen LM. Identification of cytotoxic T-cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): evidence for HLA A2 supertype- restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T-lymphocytes. Eur. J. Immunol. 28(2), 451-458 (1998).
46. Sun Q, Burton R, Reddy V, Lucas KG. Safety of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T-lymphocytes for patients with refractory EBV-related lymphoma. Br. J. Haematol. 118(3), 799-808 (2002).
47. Rooney CM, Smith CA, Ng CY et al. Infusion of cytotoxic T-cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 92(5), 1549- 1555 (1998).